Donald Rucker, former Siemens CMO, named new ONC chief

The next head of the Office of the National Coordinator for Health IT will be Donald Rucker, MD, a choice the industry was quick to praise once word of the pick leaked on March 31 due to an updated listing in the HHS employee directory.

Rucker spent 13 years as chief medical offer at Siemens from 2000 to 2013. He also served as a practicing emergency department physician for many years, holding a medical degree from the University of Pennsylvania, along with a business degree from Stanford Graduate School of Business and a computer science degree from Stanford. He currently serves as a professor of clinical emergency medicine and biomedical informatics at Ohio State University.

HHS hasn’t officially confirmed the selection, but IT industry groups seem pleased, while reserving some of their expectations until an official announcement is made.

“Donald Rucker has an extensive background in healthcare and health IT,” Matthew Weinstock, communications director for the College of Healthcare Information Management Executives (CHIME), said in a statement. “That experience on the provider and vendor side should serve him well at ONC given the agency’s role in meaningful use, especially creating EHR certification rules. As we move into the next critical stages of assessing the Meaningful Use Program, we are pleased to see the administration rounding out its health IT policy team.”

Rucker earned additional praise from a former National Coordinator for Health IT, Farzad Mostashari, MD, who tweeted, “Do good work, call on the #healthit community, we will support you.”

The future of ONC in the Trump administration has been a source of confusion. A new health technology position has been created within HHS, with former Louisiana congressman and physician, John Fleming, being appointed to the role.

In an interview with POLITICO, Fleming said he thought he was interviewing to take charge of ONC, and this new post may signal the agency will be consolidated within HHS.

“They may be reorganizing, but that’s purely speculation,” Fleming said. “No one from HHS has told me that.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.